TME Pharma N.V. announced updates on its research and development activities and its potential investment strategies. NOX-E36 developments. TME Pharma announces the initiation of a subsequent study for NOX-E36 and the simultaneous termination of its collaboration with the Singapore Eye Research Institute (SERI) for the development of NOX-E36 for glaucoma filtration surgery, as previously announced on June 18, 2025.
The end of this partnership is unrelated to the quality and potential of NOX-E36. TME Pharma is pleased to confirm its commitment to this program with the launch in January 2026 of studies to validate detection of NOX-E36 in a toxicologically relevant animal, which are the first of the studies necessary to enable local administration of NOX-E36 to patients undergoing glaucoma filtation surgery to continue advancing this promising program. The costs of this initial study are limited, and by starting the study as planned, no further delays are necessary for follow-up studies.
TME Pharma believes strongly in the potential of NOX-E 36 and by starting this new program it will become easier to find a new partner to help further the research and development of this program either in collaboration with TME Pharma or through a carveout, sale, or joint venture for NOX-E36. Fibrosis is a major contributor to glaucoma filtization surgery treatment failure and increased severity in several clinically important eye diseases with significant unmet needs, such as proliferative diabetic retinopathy and age-related macular degeneration. Collectively, these conditions affect approximately 30 million people in the US alone, with millions at risk of vision-threatening complications.
This underscores the substantial market potential for innovative anti-fibrotic therapies like NOX-E36 and The interest in a future partnership for this program. NOX-A12. TME Pharma continues its active discussions with potential partners for the NOX-A12 program.
TME Pharma has kept the clinical trial for glioblastoma open so that it can be resumed as soon as a suitable partner is found. TME Pharma expects to be able to present a clear update and strategy to the market in the coming weeks. Investment in Cryptocurrencies.
On June 30, 2025, TME Pharma announced a new treasury policy to allow investment in higher-risk assets such as crypto-currency related investments. To date, no attractive opportunity has presented itself, and the Company has not invested in the crypto markets. TME Pharma has closed the year with approximately EUR2.0 million in cash-on-hand (as compared to EUR2.06 million as at June 30, 2025), reflecting a responsible treasury policy and strict cost control.
Investment in 'GRDC' On November 5, 2025, TME Pharma announce it had signed a non-binding LOI with a 'German Resource Development Company' ('GRDC'). Discussions with this partner are still ongoing, and due diligence is underway. Only in the event that the discussions and due diligence are positive and the Company believes the transaction will create significant value, TME Pharma will submit it to the shareholders for approval.
